NCT03617341: Brain Monitoring for High Risk of Brain Metastases in Metastatic Breast Cancer

NCT03617341
Breast Cancer Type: HER2+, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Not yet recruiting

Drug Category: Other

Key Eligibility Criteria:

Gender: All
Age: 19 Years and older (Adult, Older Adult)
Location of Metastases: Brain
Additional Notes: 
Exclusions: Patients with prior treatments for brain or leptomeningeal metastases; Patients who have received more than second-line systemic treatments (including endocrine therapy)
https://ClinicalTrials.gov/show/NCT03617341

Comments are closed.

Up ↑